Steroid use in the dermatological field and actual prophylactic treatment for steroid-induced osteoporosis [in Japanese; abstract in English]
Furukawa F, Takigawa M, Katayama I. Steroid use in the dermatological field and actual prophylactic treatment for steroid-induced osteoporosis [in Japanese; abstract in English]. Nishinihon Dermatol 2002; 64: 724-45.
Actual prophylactic therapy in the dermatological field for steroid-induced osteoporosis following oral therapy (second report) [in Japanese; abstract in English]
Furukawa F, Sato S, Takigawa M. Actual prophylactic therapy in the dermatological field for steroid-induced osteoporosis following oral therapy (second report) [in Japanese; abstract in English]. Nishinihon Dermatol 2009; 71: 209-15.
Werth Cross-sectional study of bisphosphonate use in dermatology patients receiving long-term oral corticosteroid therapy
Liu RH, Albrecht J. Werth Cross-sectional study of bisphosphonate use in dermatology patients receiving long-term oral corticosteroid therapy. Arch Dermatol 2006; 142: 37-41.
Suggested rationale for prevention and treatment of glucocorticoid-induced bone loss in dermatologic patients
Yosipovitch G, Hoon TS, Leok GC. Suggested rationale for prevention and treatment of glucocorticoid-induced bone loss in dermatologic patients. Arch Dermatol 2001; 137: 477-81.
Biochemical markers of bone turnover and bone loss at the lumbar spine and femoral neck: the Taiji study
Yoshimura N, Hashimoto T, Sakata K et al. Biochemical markers of bone turnover and bone loss at the lumbar spine and femoral neck: the Taiji study. Calcif Tissue Int 1999; 65: 198-202.